Skip to content
Screener

Immunome IMNM Q1 2025 earnings

Reported May 12, 2025 · Before market open

Revenue$2.9MBeat by $2.5M
EPS-$0.52Beat by $0.14
Revenue estimate$457.1K
EPS estimate-$0.66

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$181.8K
EPS estimate-$0.64

Financials

Q1 2025

Income statement

See full
Revenue$2.9M+184%
Operating income-$44.6M+66.3%
Net income-$41.6M+67.8%
EPS (diluted)-$0.52+79.3%

Balance sheet

See full
Cash & equivalents$257.6M-4.5%
Total debt$4.8M+296%
Total equity$307.1M+7.5%
Total assets$342.7M+7.2%

Cash flow

See full
Operating cash flow-$53.1M-375%
CapEx$3.7M+69.4%
Free cash flow-$56.7M-325%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$585.18M-60.0%
Enterprise value$332.33M-72.2%
P/S53.5×-62.0×

Profitability

See full
Operating margin-1,994.3%+140pp
Net margin-1,875.2%+48.1pp
FCF margin-1,475.2%—

Returns & leverage

See full
Return on equity-69.2%-24.7pp
Debt / equity0×0.0×
Current ratio10.5×+0.3×

FAQ

When did Immunome report Q1 2025 earnings?
Immunome (IMNM) reported Q1 2025 earnings on May 12, 2025 before market open.
What were Immunome's Q1 2025 revenue and EPS?
Immunome reported revenue of $2.9M and eps of $-0.52 for Q1 2025.
Did Immunome beat estimates in Q1 2025?
Revenue beat the consensus estimate of $457.1K by $2.5M. EPS beat the consensus estimate of $-0.66 by $0.14.
How did Immunome's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 184.4% from $1.0M a year earlier and eps declined 52.9% from $-0.34.
Where can I find Immunome's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-047304) and the 10-Q periodic report (0001558370-25-007382) directly on SEC EDGAR. The filing index links above go to sec.gov.